As DDK is an obvious target for cancer therapy, information about the unique features of Dbf4 in regulating Cdc7 activities provides the necessary details for developing novel anti-cancer drugs that selectively kill cancer cells with low toxic off-target side effects. This evidence concerns the gene CDC7 and cancer.